Roheena Z Panni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6292945/publications.pdf

Version: 2024-02-01

840776 1281871 2,154 11 11 11 citations h-index g-index papers 11 11 11 4037 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Association of preoperative monocyteâ€toâ€lymphocyte and neutrophilâ€toâ€lymphocyte ratio with recurrenceâ€free and overall survival after resection of pancreatic neuroendocrine tumors (USâ€NETSG). Journal of Surgical Oncology, 2019, 120, 632-638.	1.7	30
2	Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Science Translational Medicine, 2019, 11 , .	12.4	148
3	Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2019, 23, 651-658.	1.7	15
4	Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nature Communications, 2018, 9, 1250.	12.8	151
5	Preoperative predictors of conversion as indicators of local inflammation in acute cholecystitis: strategies for future studies to develop quantitative predictors. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 101-108.	2.6	38
6	Targeting both tumour-associated CXCR2 ⁺ neutrophils and CCR2 ⁺ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut, 2018, 67, 1112-1123.	12.1	334
7	Recruitment of CCR2 ⁺ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer. Oncolmmunology, 2018, 7, e1470729.	4.6	88
8	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncology, The, 2016, 17, 651-662.	10.7	557
9	Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunology, Immunotherapy, 2014, 63, 513-528.	4.2	185
10	Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy, 2013, 5, 1075-1087.	2.0	135
11	Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis. Clinical Cancer Research, 2013, 19, 3404-3415.	7. 0	473